ALX Oncology Holdings Stock (NASDAQ: ALXO)

ALX Oncology Holdings

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

zscaler shutter2

News

Upgrades

Markets

Analyst Ratings

Trading Ideas

ALXO

CUBE

This Zscaler Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Healthcare Consulting

Long Ideas

Pre-Market Outlook

VRCA

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month

Crude-oil-4-logo

Earnings

Eurozone

Commodities

Intraday Update

ATEC

EXAS

MRNA

OMCL

RDHL

Vintage Wine Estates, Inc. - Common Stock

Crude Oil Moves Lower; Moderna Shares Plunge

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings Inc

Press Releases

ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI

Management

ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors

Small Cap

Opinion

Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in  Patients with HER2-Positive Gastric Cancer

ALX Oncology to Host Virtual R&D Day on March 5, 2025

ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Health Care

ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event

ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge

AGEN

CRDF

EXEL

ONCY

RNXT

TSX:ONC

VSTM

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Adicet Bio

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Aerovate Therapeutics, Inc. - Common Stock

Aerovate Therapeutics

Avalo Therapeutics

BeyondSpring

Cibus

Citius Oncology

Cue Biopharma

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

iBio

I-MAB

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

IO Biotech

Metagenomi

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

Mural Oncology

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

PMV Pharma

Pyxis Oncology

Quince Therapeutics

Shattuck Labs

Tenaya Therapeutics

X4 Pharmaceuticals

Stifel

HC Wainwright & Co.

Piper Sandler

Jefferies

Comments

ALX Oncology Holdings

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga